Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 53, Issue 2, 2002, Pages 133-139

  Swart, Eleonora L ^a   Van Der Hoven, Ben ^a   Groeneveld, A B Johan ^a   Touw, Daniel J ^a   Danhof, Meindert ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

CYP3A4; Erythromycin; Lignocaine; MEGX; Midazolam; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 3A4; DEETHYLLIDOCAINE; ENZYME INHIBITOR; ERYTHROMYCIN ETHYLSUCCINATE; LIDOCAINE; MIDAZOLAM; MIDAZOLAM MALEATE;

ACCURACY; ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; LIVER CLEARANCE; LIVER FUNCTION TEST; MALE; METABOLITE; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; VENOUS BLOOD;

ADULT; DRUG INTERACTIONS; ERYTHROMYCIN; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; LIDOCAINE; LIVER FUNCTION TESTS; MALE; MIDAZOLAM; TIME FACTORS;

EID: 0036202994     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01182.x     Document Type: Article

References (30)

1. Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients
2. Midazolam infusions in critically ill patients
3. Continuous intravenous infusions of lorazepam versus midazolam for sedation during mechanical ventilatory support: A prospective, randomized study
4. Complications of sedation with midazolam in the intensive care unit and a comparison with other sedative regimens
5. Continuous infusion of lorazepam vs midazolam in patients in the intensive care unit: Sedation with lorazepam is easier to manage and is more cost-effective
6. Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability?
7. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis
8. What changes drug metabolism in critically ill patients-III? Effect of pre-existing disease on the metabolism of midazolam
9. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects
10. Use of midazolam as a human cytochrome P 450, 3A probe. I. In vitro-in vivo correlations in liver transplant patients
11. Determination of midazolam and its 1-hydroxymetabolite in human plasma and urine by high-performance liquid chromatography
12. High performance liquid chromatographic assay of midazolam and flumazenil simultaneously in human plasma
13. Monoethylglycinexylidide formation kinetics. A novel approach to assessment of liver function
14. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis
15. Measuring lidocaine metabolite - Monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis
16. MEGX (monoethylglycinexylidide): A novel in vivo test to measure early hepatic dysfunction after hypovolemic shock
17. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine
18. HMG-CoA reductase inhibitors. Assessing differences in drug interactions and safety profiles
19. A potentially hazardous interaction between erythromycin and midazolam
20. Clinically important interaction between erythromycin and midazolam
21. Influence of the antibiotics erythromycin and azitromycin on the pharmacokinetics and pharmacodynamics of midazolam
22. The effect of liver disease and food on plasma MEGX concentrations
23. Effect of food on lidocaine kinetics: Mechanism of food-related alteration in high intrinsic clearance drug elimination
24. Physiologic and temporal variation in hepatic elimination of midazolam
25. Assessment of the hepatic circulation in humans: New concepts based on evidence derived from a D-sorbitol clearance method
26. CYP3A4 drug interactions, correlation of 10 in vitro probe substrates
27. Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans
28. Extrahepatic production of the lignocaine metabolite monoethylglycinexylidide (MEGX)
29. Influence of gender on the monoethylglycinexylidide test in normal subjets and liver donors
30. Effect of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics